Navigation Links
Nonconformity of NOV002 Used in Phase 3 NSCLC Trial Sponsored by Novelos Therapeutics, Inc to NOV002 (Glutoxim(R)), Used in Phase 1/2 NSCLC and all Previous Trials
Date:6/29/2010

SAINT PETERSBURG, June 29, 2010 /PRNewswire/ -- The Company VAM is the developer of product Glutoxim(R) registered in Russia in 1998, registration No. P N002010/01. We possess significant knowledge and experience in manufacturing of this product as well as in the clinical development application of Glutoxim(R). In accordance with an Agreement dated June 20, 2000, the company VAM diligently and successfully transferred all of the "know-how", manufacturing and quality assurance information on the active drug substance and finished injection forms of the product Glutoxim(R) to Novelos Therapeutics, Inc.

Up to October 2005, the active pharmaceutical ingredient used in Glutoxim(R) (US code name NOV002) was synthesized according to the original manufacturing process and technology transferred from the company VAM to Novelos. The original NOV002 (Glutoxim(R)) used in the Phase 1/2 NSCLC and all previous trials met predetermined clinical endpoints and yielded encouraging results.

After the completion of the Phase 3 NSCLC trial and learning that NOV002 had failed to meet clinical endpoints, VAM requested Novelos to provide samples of products used in the Phase 3 trial. At VAM's request, an independent chemical and biological analysis of the samples was performed in the State Technological Institute of Saint-Petersburg and State Research Trial Institute of Military Medicine.

Expert opinions - excerpts[1]

Technological Institute

"On the basis of data generated by the element analysis it is possible to make a conclusion, that all three presented dry samples considerably differ from each other on parity of Pt:Fe which varies from ~ 2 to 70 atoms of platinum on 1 atom of Iron. Such appreciable variance in comparability of concentrations of iron and platinum testifies that it is impossible to consider all products standardized.

In spite of the fact that according to IR and a nuclear magnetic resonance spectroscopy on kernels 1H and 13C supplied samples of NOV002 contain pure enough disodium salt of oxidized glutathione, they do not correspond to Glutoxim(R) due to the high concentration of iron (II) that destabilizes action of platinum complex, which proves to be true on the basis of quantum chemical DFT calculations"

Trial Institute of Military Medicine

"The comparative assessment of hemostimulating activity of 3 presented samples (Lots 05, 06, 07) of NOV002 and Glutoxim(R) was performed using a model of Cyclophosphamide induced hemodepression. Research results have shown:

    1. Essentially differing hemostimulating activity between 3 presented
       samples.

    2. Target effect was reached in groups with Glutoxim(R) and Lot 05.

    3. In the groups receiving Lot 06 and Lot 07 physiologically incompatible
       stimulation of hematopoiesis, led to deterioration of rheological
       blood properties and, as consequence, death of study animals that
       raises requirements in an assessment of their safety."

On recently, in 2010, VAM became aware that in August of 2005, Novelos had modified manufacturing process and quality assurance specifications for the NOV002 that was used in the Phase 3 NSCLC trial. Novelos undertook these changes without the corresponding coordination with VAM, original developer.

To the best of our knowledge Novelos had not conducted any preclinical or clinical studies of the newly synthesized active pharmaceutical ingredient before initiating the Phase 3 clinical trial. As noted above, the Phase 3 NSCLC trial using the modified active pharmaceutical ingredient failed to meet clinical endpoints. The original NOV002 (Glutoxim(R)) used in the Phase 1/2 NSCLC and all previous trials met predetermined clinical endpoints and yielded encouraging results.

VAM firmly believes that it is our obligation and ethical duty to inform the oncology community regarding of the modification and nonconformity of the Novelos NOV002 product used in the Phase 3 NSCLC trial as compared to the NOV002 (VAM Glutoxim(R)) product used in the Phase 1/2 NSCLC trial and all preceding clinical and preclinical studies that served as the basis for the IND package compilation.

---------------------------------

[1] Full reports are on file at VAM.

T: +7-812-714-1010, email: info@glutoxim.ru, http://www.glutoxim.ru


'/>"/>
SOURCE Pharma Vam
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... FinancialBuzz.com News Commentary  ... Based on New Frontier Data,s sales forecasts in 2017, estimates ... generate $655 million in taxes on retail sales. Out of this ... Washington State,s 37% cannabis retail tax rate. ... that are applied on all retail sales. By 2020, tax revenues ...
(Date:3/27/2017)... , March 27, 2017 BioLineRx ... and immunology, announced today that AGI-134, an immunotherapy for the ... of Agalimmune Ltd., will be featured at the upcoming ... Washington, DC to be held on ... ...
(Date:3/27/2017)... 27, 2017   Pulmatrix, Inc . (NASDAQ: PULM), a ... serious pulmonary diseases, today announced that it has added two ... and asthma to its Scientific Advisory Board . ... Richard B. Moss , MD, former chief of the Pediatric ... Fibrosis Center at Stanford University, and ...
Breaking Medicine Technology:
(Date:3/27/2017)... California (PRWEB) , ... March 27, 2017 , ... The ... to its customers. First National Capital has added 10 new sales professionals over the ... its sales positions by 15 additional new hires over the course of 2017. ...
(Date:3/27/2017)... Mt. Angel, Oregon (PRWEB) , ... March 27, ... ... supplements company, is pleased to announce the launch of a months-long rebranding effort. ... exciting new formulations. , “Through focus group discussions and market research, we learned ...
(Date:3/27/2017)... ... March 27, 2017 , ... Golden Triangle Emergency Center ... Monday, April 3rd to commemorate the two-year anniversary of the facility. The event ... celebrate two great years while also familiarizing themselves with the facility. , In ...
(Date:3/27/2017)... ... ... The homeowner improvement and repair market is expected to reach $317 billion ... renovations is also on the rise. Per a 2017 report, 13% of all households ... to use a licensed contractor.(2) The risks associated with improper renovations—especially tiling—can not only ...
(Date:3/26/2017)... ... March 26, 2017 , ... Local physician Dr. Justin Harper ... prestigious award honoring the top influencers on RealSelf—the most trusted online destination to ... and clinics. , In 2016, more than 82 million people visited RealSelf to ...
Breaking Medicine News(10 mins):